[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470521":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":26,"centralContacts":34,"locations":10,"responsibleParty":40,"collaborators":43,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":10},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low risk group",null,"Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.",[13],"Other: Prospective observational study, no intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Middle risk group","Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High risk group","Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.",[13],[23],{"type":6,"name":24,"description":24,"armGroupLabels":25,"otherNames":10},"Prospective observational study, no intervention",[19,9,15],[27,31],{"name":28,"affiliation":29,"role":30},"Yongji Tian, MD","Beijing TianTanHospital, China Capital Medical University","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":33,"role":30},"FU ZHAO, MD","Beijing Neurosurgical Institute",[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"yongji TIAN, MD","CONTACT","15801593549","tianyongji@bjtth.org",{"type":30,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Tianyongji","Director",[44,45,47,49,51],{"name":33,"class":6},{"name":46,"class":6},"Beijing Children's Hospital",{"name":48,"class":6},"Beijing Shijitan Hospital, Capital Medical University",{"name":50,"class":6},"Xuanwu Hospital, Beijing",{"name":52,"class":6},"Peking University Third Hospital","100470521",false,"NCT05406947","Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children","Inclusion Criteria:\n\n* Age 0.5-18 years (except neonates).\n* Pathologically confirmed medulloblastoma.\n* Not having received any other relevant treatment before surgery.\n* Completion of enhanced MRI of the head and spinal cord.\n* Availability of tumor samples and determination of molecular typing.\n* Postoperative KPS score ≥ 70.\n* Voluntary enrollment in the group and the ability to receive long-term follow-up.\n* The patient or the patient's family voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have recently received other drugs or radiation therapy.\n* Patients suffering from acute or chronic infectious diseases\n* Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.\n* Patients who cannot receive enhanced MRI scans.\n* Other conditions that the investigator believes make the patient unfit to participate in this trial.","ALL","6 Months","18 Years",{"count":62,"type":63},350,"ESTIMATED","OBSERVATIONAL","The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.",[67],"Medulloblastoma, Childhood",[69,70,71,72],"Medulloblastoma","Glioma","Medulloblastoma, Childhood, Recurrent","Neuroepithelioma","NOT_YET_RECRUITING","2023-02-06",{"date":76,"type":77},"2023-02-08","ACTUAL",{"date":79,"type":63},"2023-01-30",{"date":81,"type":63},"2030-12-31",{"name":5,"class":6}]